This is important. Higher doses of adalimumab (Humira) were not more effective for INDUCTION of remission of #UC (and similarly presented this week, #Crohns) despite higher serum concentrations of drug. Maintenance study is ongoing. #UEGW2019
We will discuss further at #ACG2019 https://t.co/BFOgQfzKsZ